Fortrea Expands Patient Access and Cold Chain Expertise with FortreaRx expansion, while Partnering with Veeva and Advarra for Streamlined Clinical Trial Experience
In a recent press release, Fortrea announced its expansion of the non-commercial specialty pharmacy, FortreaRx, to enhance patient access capabilities and further develop its cold chain expertise. The expansion aims to deliver flexible and scalable solutions to customers, ensuring life-changing medications are directly available to patients.
With the growing demand for specialty medications, patient access and logistics management have become essential factors in healthcare. Fortrea recognized the need to enhance its capabilities in this area, leading to the expansion of FortreaRx. This move will enable the company to meet the evolving needs of patients and healthcare providers, ensuring the timely delivery of critical medications to those who need them most.
By expanding FortreaRx, Fortrea has taken a significant step towards improving patient access to specialized pharmaceuticals. The expansion will enable the company to streamline the process of medication delivery, providing patients with easy access to the drugs they require for improved health outcomes. Additionally, the expansion will enhance Fortrea’s cold chain expertise, ensuring the safe and effective transport and storage of temperature-sensitive medications.
Fortrea has also prioritized the improvement of the clinical trial experience for both patients and research sites. In a previous announcement, the company established an industry partnership with Veeva and Advarra. This partnership aims to provide patients and research sites with easy access to study information through an integrated solution. By streamlining the process, Fortrea, Veeva, and Advarra are empowering patients to stay informed about ongoing clinical trials, facilitating participation and ensuring a seamless experience for sites involved in research.
In parallel news, the Vietnam Chamber of Commerce and Industry (VCCI) released the Mekong Delta Annual Economic Report 2023. This report is a significant outcome of the responsibilities mandated by the Government Resolution 57/NQ-CP from 2022. The VCCI, as the lead organization, collaborated with relevant agencies to autonomously monitor, assess, and report on the socio-economic progress of the region. The report focuses on evaluating the effectiveness of regional coordination and linkage activities in each locality as outlined in the resolution.
The Mekong Delta Annual Economic Report 2023 sheds light on the progress made in the region’s socio-economic development. By assessing regional coordination and linkage activities, policymakers and stakeholders can make informed decisions to further boost economic growth and prosperity in the Mekong Delta area. The report serves as a valuable resource for understanding the region’s challenges and opportunities, enabling targeted interventions for improvement.
In summary, Fortrea’s expansion of FortreaRx demonstrates the company’s commitment to enhancing patient access to life-changing medications. The partnership with Veeva and Advarra further contributes to improving the clinical trial experience for patients and research sites. Meanwhile, the release of the Mekong Delta Annual Economic Report 2023 provides valuable insights into the region’s economic development. These advancements and collaborations signify Fortrea’s dedication to improving healthcare delivery and fostering economic growth in Vietnam’s Mekong Delta.
Comments